Skip to main navigation Skip to search Skip to main content

Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients

  • University Health Network University of Toronto
  • Azienda Ospedaliera Universitaria Senese

Research output: Contribution to journalArticle

Abstract

Immunogenicity of influenza A (H1N1)v MF59-adjuvanted vaccine was studied in HIV-infected patients. The vaccine was effective in inducing a protective immune response in patients with a CD4 >200. cells/μL while individuals with CD4 <200. cells/μL showed lower rates of seroconversion and seroprotection. These results underscore the usefulness of immunization against influenza in HIV-infected patients, though a boosting dose of vaccine may be required in seriously immunocompromised patients. © 2011 Elsevier Ltd.
Original languageEnglish
Pages (from-to)2836-2839
Number of pages4
JournalVaccine
Volume29
Issue number16
DOIs
Publication statusPublished - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • General Immunology and Microbiology
  • General Veterinary
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Keywords

  • Adjuvants
  • Adult
  • Antibodies
  • CD4 Lymphocyte Count
  • Environmental and Occupational Health
  • Female
  • H1N1 Subtype
  • HIV
  • HIV Infections
  • Hemagglutinin Glycoproteins
  • Human
  • Humans
  • Immunogenicity
  • Immunologic
  • Immunology and Microbiology (all)
  • Infectious Diseases
  • Influenza
  • Influenza A (H1N1)
  • Influenza A Virus
  • Influenza Vaccines
  • Influenza Virus
  • Male
  • Middle Aged
  • Molecular Medicine
  • Polysorbates
  • Public Health
  • Squalene
  • Swine flu
  • Vaccination
  • Veterinary (all)
  • Viral

Fingerprint

Dive into the research topics of 'Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients'. Together they form a unique fingerprint.

Cite this